|
[1]
|
Chen, J., Wei, Z., Fu, K., et al. (2022) Non-Apoptotic Cell Death in Ovarian Cancer: Treatment, Resistance and Progno-sis. Biomedicine & Pharmacotherapy, 150, Article ID: 112929. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
马小鸿, 姜洁. 卵巢癌靶向治疗进展[J]. 中国医刊, 2021, 56(4): 352-356.
|
|
[3]
|
Kehoe, S., Hook, J., Nankivell, M., et al. (2015) Primary Chemotherapy versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Randomised, Controlled, Non-Inferiority Trial. The Lancet, 386, 249-257. [Google Scholar] [CrossRef]
|
|
[4]
|
Onda, T., Satoh, T., Saito, T., et al. (2016) Comparison of Treatment Invasiveness between Upfront Debulking Surgery versus Interval Debulking Surgery following Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal, and Peritoneal Cancers in a Phase III Randomised Trial: Japan Clinical Oncology Group Study JCOG0602. European Journal of Cancer, 64, 22-31. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wang, H., Fan, L., Wu, X., et al. (2022) Efficacy Evaluation of Al-bumin-Bound Paclitaxel Combined with Carboplatin as Neoadjuvant Chemotherapy for Primary Epithelial Ovarian Can-cer. BMC Women’s Health, 22, Article No. 224. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Group, I.C.O.N. (2002) Paclitaxel plus Carboplatin versus Standard Chemotherapy with Either Single-Agent Carboplatin or Cyclophosphamide, Doxorubicin, and Cisplatin in Women with Ovarian Cancer: The ICON3 Randomised Trial. The Lancet, 360, 505-515. [Google Scholar] [CrossRef]
|
|
[7]
|
Aravantinos, G., Fountzilas, G., Kosmidis, P., et al. (2005) Paclitaxel plus Carboplatin versus Paclitaxel plus Alternating Carboplatin and Cisplatin for Initial Treatment of Advanced Ovarian Cancer: Long-Term Efficacy Results: A Hellenic Cooperative Oncology Group (HeCOG) Study. Annals of On-cology, 16, 1116-1122. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Bookman, M.A., Brady, M.F., McGuire, W.P., et al. (2009) Evalua-tion of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gyneco-logic Cancer Intergroup. Journal of Clinical Oncology, 27, 1419-1425. [Google Scholar] [CrossRef]
|
|
[9]
|
Hoskins, P., Vergote, I., Cervantes, A., et al. (2010) Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Car-boplatin-Paclitaxel. Journal of the National Cancer Institute, 102, 1547-1556. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Vasey, P.A., Jayson, G.C., Gordon, A., et al. (2004) Phase III Random-ized Trial of Docetaxel-Carboplatin versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma. JNCI: Journal of the National Cancer Institute, 96, 1682-1691. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Pignata, S., Scambia, G., Ferrandina, G., et al. (2011) Carboplatin plus Paclitaxel versus Carboplatin plus Pegylated Liposomal Dox-orubicin as First-Line Treatment for Patients with Ovarian Cancer: The MITO-2 Randomized Phase III Trial. Journal of Clinical Oncology, 29, 3628-3635. [Google Scholar] [CrossRef]
|
|
[12]
|
Katsumata, N., Yasuda, M., Isonishi, S., et al. (2013) Long-Term Results of Dose-Dense Paclitaxel and Carboplatin versus Conventional Paclitaxel and Carboplatin for Treatment of Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (JGOG 3016): A Randomised, Controlled, Open-Label Trial. The Lancet Oncology, 14, 1020-1026. [Google Scholar] [CrossRef]
|
|
[13]
|
Chan, J.K., Brady, M.F. and Monk, B.J. (2016) Weekly vs. Every-3-Week Paclitaxel for Ovarian Cancer. The New England Journal of Medicine, 374, 2603-2604. [Google Scholar] [CrossRef]
|
|
[14]
|
Pignata, S., Scambia, G., Katsaros, D., et al. (2014) Carboplatin plus Paclitaxel Once a Week versus Every 3 Weeks in Patients with Advanced Ovarian Cancer (MITO-7): A Randomised, Multicentre, Open-Label, Phase 3 Trial. The Lancet Oncology, 15, 396-405. [Google Scholar] [CrossRef]
|
|
[15]
|
Blagden, S.P., Cook, A.D., Poole, C., et al. (2020) Weekly Platinum-Based Chemotherapy versus 3-Weekly Platinum-Based Chemotherapy for Newly Diagnosed Ovarian Cancer (ICON8): Quality-Of-Life Results of A Phase 3, Randomised, Controlled Trial. The Lancet Oncology, 21, 969-977. [Google Scholar] [CrossRef]
|
|
[16]
|
Yang, X. and Fu, C. (2022) The Potential Feasibility of Nab-Paclitaxel as the First-Line Chemotherapy for Ovarian Cancer: Clinical Development and Future Perspectives. Ar-chives of Gynecology and Obstetrics, 306, 1417-1429. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Wang, L., Li, S., Zhu, D., et al. (2023) Effectiveness and Safety of Nab-Paclitaxel and Platinum as First-Line Chemotherapy for Ovarian Cancer: A Retrospective Study. Journal of Gy-necologic Oncology, 34, e44. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Dou, Y. and Jiang, D. (2021) Research Progress of Small Molecule Anti-Angiogenic Drugs in Non-Small Cell Lung Cancer. Chinese Journal of Lung Cancer, 24, 56-62.
|
|
[19]
|
Perren, T.J., Swart, A.M., Pfisterer, J., et al. (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. The New England Journal of Medicine, 365, 2484-2496. [Google Scholar] [CrossRef]
|
|
[20]
|
Oza, A.M.P., Cook, A.D.M., Pfisterer, J.P., et al. (2015) Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. The Lancet Oncology, 16, 928-936. [Google Scholar] [CrossRef]
|
|
[21]
|
Burger, R.A., Brady, M.F., Bookman, M.A., et al. (2011) Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. The New England Journal of Medicine, 365, 2473-2483. [Google Scholar] [CrossRef]
|
|
[22]
|
Tewari, K.S., Burger, R.A., Enserro, D., et al. (2019) Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. Journal of Clin-ical Oncology, 37, 2317-2328. [Google Scholar] [CrossRef]
|
|
[23]
|
Garcia Garcia, Y., De Juan FerrÉ, A., Mendiola, C., et al. (2019) Effi-cacy and Safety Results from GEICO 1205, a Randomized Phase II Trial of Neoadjuvant Chemotherapy with or without Bevacizumab for Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 29, 1050-1056. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Rouzier, R., Gouy, S., Selle, F., et al. (2017) Efficacy and Safety of Bevacizumab-Containing Neoadjuvant Therapy Followed by Interval Debulking Surgery in Advanced Ovarian Cancer: Results from the ANTHALYA Trial. European Journal of Cancer, 70, 133-142. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Moore, K., Colombo, N., Scambia, G., et al. (2018) Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England Journal of Medicine, 379, 2495-2505. [Google Scholar] [CrossRef]
|
|
[26]
|
Pujade-Lauraine, E., Ledermann, J.A., Selle, F., et al. (2017) Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet On-cology, 18, 1274-1284. [Google Scholar] [CrossRef]
|
|
[27]
|
Gonzalez-Martin, A., Pothuri, B., Vergote, I., et al. (2019) Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England Journal of Medicine, 381, 2391-2402. [Google Scholar] [CrossRef]
|
|
[28]
|
Moore, K.N., Secord, A.A., Geller, M.A., et al. (2019) Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): A Multicentre, Open-Label, Sin-gle-Arm, Phase 2 Trial. The Lancet Oncology, 20, 636-648. [Google Scholar] [CrossRef]
|
|
[29]
|
Varga, A., Piha-Paul, S., Ott, P.A., et al. (2019) Pembroli-zumab in Patients with Programmed Death Ligand 1—Positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028. Gynecologic Oncology, 152, 243-250. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Uyar, D., Michener, C.M., Bradley, W.H., et al. (2020) Prelimi-nary Results from Phase II Trial of Pembrolizumab with First Line Platinum Based Chemotherapy followed by Mainte-nance Pembrolizumab for Patients with Suboptimally Cytoreduced Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 159, 146-147. [Google Scholar] [CrossRef]
|
|
[31]
|
Westin, S.N., Moore, K., Chon, H.S., et al. (2023) Durvalumab plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab with or without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. Journal of Clinical Oncology, 42, 283-299.
|
|
[32]
|
Gaillard, S., Duska, L., Broadwater, G., et al. (2021) AdoRN Trial: Atezolizumab in Combination with Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients with Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer. Gy-necologic Oncology, 162, S61. [Google Scholar] [CrossRef]
|
|
[33]
|
Kako, T., Dholakia, J., Leath, C., et al. (2022) Single-Arm Phase II Trial of Carboplatin and Mirvetuximab Soravtansine as Neoadjuvant Chemotherapy (NACT) for Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer (EOC) Who Are Folate Receptor α Positive (NCT04606914) (578). Gynecologic Oncology, 166, S281. [Google Scholar] [CrossRef]
|
|
[34]
|
Ray-Coquard, I., Pautier, P., Pignata, S., et al. (2019) Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. The New England Journal of Medicine, 381, 2416-2428. [Google Scholar] [CrossRef]
|
|
[35]
|
Mirza, M.R., Bergmann, T.K., Mau-Sorensen, M., et al. (2019) A Phase I Study of the PARP Inhibitor Niraparib in Combination with Bevacizumab in Platinum-Sensitive Epi-thelial Ovarian Cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology, 84, 791-798. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Zhu, X. and Lang, J. (2017) Programmed Death-1 Pathway Blockade Produces a Synergistic Antitumor Effect: Combined Application in Ovarian Cancer. Journal of Gynecologic Oncology, 28, e64. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Konstantinopoulos, P.A., Waggoner, S., Vidal, G.A., et al. (2019) Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Plati-num-Resistant Ovarian Carcinoma. JAMA Oncology, 5, 1141-1149. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Domchek, S.M., Postel-Vinay, S., Im, S.A., et al. (2020) Olaparib and Durvalumab in Patients with Germline BRCA-Mutated Metastatic Breast Cancer (MEDIOLA): An Open-Label, Multicentre, Phase 1/2, Basket Study. Lancet Oncology, 21, 1155-1164. [Google Scholar] [CrossRef]
|